<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92289">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01750554</url>
  </required_header>
  <id_info>
    <org_study_id>10-00524D</org_study_id>
    <nct_id>NCT01750554</nct_id>
  </id_info>
  <brief_title>The Influence of a Bupivacaine Digital Nerve Block Using Rev G.</brief_title>
  <official_title>The Influence of a Bupivacaine Digital Nerve Block With the New Continuous Sensor (Rev G) on the Accuracy of SpHb Monitoring.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are proposing to continue investigation to improve the accuracy of the
      SpHb (continuous hemoglobin monitoring device) by administering an intermediate acting
      digital nerve block in the finger connected to the SpHb, specifically bupivacaine 0.25% in
      patients undergoing spine surgery.  Bupivacaine is FDA approved and in routine use.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing spine surgery will be randomized to receive (or not) the bupivacaine
      digital block on the finger attached to the new limited release version of the hemoglobin
      sensor, RevG.   The SpHb reading will be compared to a blood hemoglobin level analyzed in
      the UCSF Clinical Laboratories.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>SpHb (continuous hemoglobin monitor reading) minus tHb (clinical laboratory determined hemoglobin value).</measure>
    <time_frame>Intermittent (about hourly) hemoglobin checks throughout the surgery.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Use of a longer acting local anesthetic (bupivacaine) for the digital nerve block will result in SpHb (the non-invasive hemoglobin device) being sufficiently accurate for blood transfusion decisions(â‰¤ 1.0 g/dL difference)
To assess if using an intermediate-acting digital nerve block will improve the accuracy of the SpHb readings when compared to a blood hemoglobin level analyzed in the UCSF Clinical Laboratories intermittently during the patient's surgery.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Patients Undergoing Spine Surgery</condition>
  <arm_group>
    <arm_group_label>bupivacaine digital nerve block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergoing spine surgery will have a 50/50 chance of being randomized to receive a bupivacaine 0.25% (2 milliliters total) digital nerve block.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No bupivacaine digital nerve block</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients undergoing spine surgery will have a 50/50 chance of being randomized to not receive a bupivacaine 0.25% (2 milliliters total) digital nerve block.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <arm_group_label>bupivacaine digital nerve block</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female 18 years of age or older

          -  American Society of Anesthesiologists classification 1, 2 or 3

          -  Scheduled to undergo spine or hip surgery

        Exclusion Criteria:

          -  Pregnant or nursing

          -  Patients who in the study investigators clinical judgement would not be suitable
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald D Miller, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 2, 2013</lastchanged_date>
  <firstreceived_date>December 10, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SpHb; hemoglobin monitoring;bupivacaine digital nerve block</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
